Amolyt Pharma, a Portfolio Company of Andera Partners, Acquired by AstraZeneca

AstraZeneca has acquired all outstanding shares of Amolyt Pharma for up to $1.05 billion. Andera Partners, a European private equity firm, confirmed the acquisition.

Based in Paris, Lyon, and Cambridge, MA, Amolyt Pharma is a clinical-stage biopharmaceutical company. It specializes in developing therapeutic peptides for rare endocrine and related diseases.

This acquisition enhances AstraZeneca's Alexion rare disease division. It adds eneboparatide (AZP-3601), a Phase III investigational drug for hypoparathyroidism, to its pipeline.

The deal includes $800 million upfront and a potential $250 million contingent payment. This additional amount is tied to achieving a certain regulatory milestone.

Amolyt Pharma’s expertise and pipeline will support Alexion's expansion in rare endocrinology. The company aims to address significant medical needs in this field.